All Press Releases
Yuexiu REIT Wins the Best ESG (Social) Award at 9th Investor Relations Awards
Yuexiu Real Estate Investment Trust
•
Jun 30, 2023 09:59 HKT/SGT
Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, stock code: 405. HK) received the "Best ESG (Social) Award" for its outstanding social responsibility performance at the 9th Hong Kong Investor Relations Awards (the "Awar
达丰设备服务有限公司公布2022/23全年业绩
Tat Hong Equipment Service Co., Ltd
•
Jun 29, 2023 23:02 HKT/SGT
达丰设备服务有限公司（“达丰”或“公司”，连同其附属公司统称“集团”）（股份代号：2153）为在中国成立的首家外资塔式起重机服务供货商，公布其截至2023年3月31日止年度（“2023财年”或“年内”）的全年业绩。2023财年，集团的收益为人民币770.8百万元，较截至2022年3月31日止年度减少人民币96.3百万元或11.1%。公司权益持有人应占亏损为人民币35.8百万元，而截至2022年3月31日止年度的纯利约人民币47.6百万元。该减少主要由于(i)外币贷款及其他外汇风险产生的汇兑亏损大幅增加约人民币37.2百万元；及(ii)2019冠状病毒病疫情爆发及相应的控制措施（特别是在华东地区
達豐設備服務有限公司公佈2022/23全年業績
Tat Hong Equipment Service Co., Ltd
•
Jun 29, 2023 23:01 HKT/SGT
達豐設備服務有限公司（“達豐”或“公司”，連同其附屬公司統稱“集團”）（股份代號：2153）為在中國成立的首家外資塔式起重機服務供應商，公佈其截至2023年3月31日止年度（“2023財年”或“年內”）的全年業績。2023財年，集團的收益為人民幣770.8百萬元，較截至2022年3月31日止年度減少人民幣96.3百萬元或11.1%。公司權益持有人應占虧損為人民幣35.8百萬元，而截至2022年3月31日止年度的純利約人民幣47.6百萬元。該減少主要由於(i)外幣貸款及其他外匯風險產生的匯兌虧損大幅增加約人民幣37.2百萬元；及(ii)2019冠狀病毒病疫情爆發及相應的控制措施（特別是在華東地區
Tat Hong Equipment Service Co., Ltd. Announces 2022/23 Annual Results
Tat Hong Equipment Service Co., Ltd
•
Jun 29, 2023 23:00 HKT/SGT
Tat Hong Equipment Service Co., Ltd. ("Tat Hong" or the "Company", together with its subsidiaries, the "Group") (Stock Code: 2153), the first foreign-owned tower crane service provider established in the PRC, has announced its annual results for the year ended 31 March
AEON信贷财务二零二三/二四年第一季度收入跃升36.2％至380,000,000港元，溢利增加17.3％至97,000,000港元
AEON Credit Service (Asia) Company Limited
•
Jun 29, 2023 22:42 HKT/SGT
AEON信贷财务（亚洲）有限公司（“AEON信贷财务”或“集团”；股份代号：00900）今日公布截至二零二三年五月三十一日止三个月（“二零二三年第一季度”或“报告期间”）的业绩。 于二零二三年第一季度,集团的收入按年上升36.2％ 至380,000,000港元，扣除减值亏损及减值准备前的营运溢利上升39.4％至177,000,000港元。同时，除税后溢利上升17.3％至97,000,000港元，每股盈利增加至23.16港仙（二零二二年第一季度：19.74港仙）。报告期间，集团继续运用针对性营销及成功的推广活动来提振销售和应收账款增长势头，使整体销售额比去年第一季度（“二零二二年第一季度”或“去
AEON信貸財務二零二三/二四年第一季度收入躍升36.2％至380,000,000港元，溢利增加17.3％至97,000,000港元
AEON Credit Service (Asia) Company Limited
•
Jun 29, 2023 22:41 HKT/SGT
AEON信貸財務（亞洲）有限公司（「AEON信貸財務」或「集團」；股份代號：00900）今日公佈截至二零二三年五月三十一日止三個月（「二零二三年第一季度」或「報告期間」）的業績。於二零二三年第一季度,集團的收入按年上升36.2％ 至380,000,000港元，扣除減值虧損及減值準備前的營運溢利上升39.4％至177,000,000港元。同時，除稅後溢利上升17.3％至97,000,000港元，每股盈利增加至23.16港仙（二零二二年第一季度：19.74港仙）。報告期間，集團繼續運用針對性營銷及成功的推廣活動來提振銷售和應收賬款增長勢頭，使整體銷售額比去年第一季度（「二零二二年第一季度」或「去年
AEON Credit Revenue Jumps 36.2% to HK$380.0 Million in First Quarter of 2023/24, Profit Increases by 17.3% to HK$97.0 Million
AEON Credit Service (Asia) Company Limited
•
Jun 29, 2023 22:40 HKT/SGT
AEON Credit Service (Asia) Company Limited ("AEON Credit" or the "Group"; Stock Code: 00900) today announced its results for the three months ended 31 May 2023 ("Q12023" or the "Reporting Period"). In Q12023, the Group's revenue climbed by 36.2% year-on-
维珍妮2023财年收入及经调整纯利达78.8亿港元及4.6亿港元，总派息10.3港仙，分派比率超纯利30%
Regina Miracle International (Holdings) Limited
•
Jun 29, 2023 21:02 HKT/SGT
全球领先的贴身内衣创新设计制造商（Innovative Design Manufacturer，「IDM」）维珍妮国际（控股）有限公司（「维珍妮」或「公司」，连同其附属公司，统称「集团」）（股份代号：2199）公布截至2023年3月31日止年度（「回顾年内」或「2023财年」）全年业绩。回顾年内，贸易往来和物流运输逐渐恢复畅顺，消费场景多元化发展，使得集团于2023财年上半年创造了历史性的最佳业务表现。惟受全球经济不确定性的影响，上下半年度波动较大，在各半年度此消彼长的情况下，集团全年录得收入约港币7,879.3百万元（2022财年：港币8,346.7百万元），按年减少5.6%。毛利减少7.0
維珍妮2023財年收入及經調整純利達78.8億港元及4.6億港元，總派息10.3港仙，分派比率超純利30%
Regina Miracle International (Holdings) Limited
•
Jun 29, 2023 21:01 HKT/SGT
全球領先的貼身內衣創新設計製造商（Innovative Design Manufacturer，「IDM」）維珍妮國際（控股）有限公司（「維珍妮」或「公司」，連同其附屬公司，統稱「集團」）（股份代號：2199）公佈截至2023年3月31日止年度（「回顧年內」或「2023財年」）全年業績。回顧年內，貿易往來和物流運輸逐漸恢復暢順，消費場景多元化發展，使得集團於2023財年上半年創造了歷史性的最佳業務表現。惟受全球經濟不確定性的影響，上下半年度波動較大，在各半年度此消彼長的情況下，集團全年錄得收入約港幣7,879.3百萬元（2022財年：港幣8,346.7百萬元），按年減少5.6%。毛利減少7.0
Regina Miracle Records Revenue of HK$7.88 Billion and Adjusted Net Profit of HK$460 Million for Fiscal 2023, Recommends Total Dividend of HK 10.3 Cents, Distributing No Less than 30% of Net Profit
Regina Miracle International (Holdings) Limited
•
Jun 29, 2023 21:00 HKT/SGT
Regina Miracle International (Holdings) Limited ("Regina Miracle" or the "Company", together with its subsidiaries, the "Group") (HKEX: 2199), a leading global intimate wear company boasting an innovative design manufacturer ("IDM") business model, has announc
新传企划公布香港联交所主板上市计划
Emperor International Holdings Limited
•
Jun 29, 2023 20:35 HKT/SGT
香港知名数码媒体旗舰集团新传企划有限公司(「新传企划」或「本集团」，股份代号：1284.HK)今天公布其股份发售(「股份发售」)及计划于香港联合交易所有限公司(「香港联交所」)主板上市之详情。新传企划透过股份发售发行合共1.5亿新股股份，包括1.35亿股配售股份予投资者认购及1,500万股予香港公众认购(「股份分配」)，即分别占总发售股份数目90%及10%。发售股份之股份分配将视乎情况重新分配，倘公开发售获某程度的超额认购，部份股份将从配售重新分配至公开发售。英皇企业融资有限公司及力高企业融资有限公司为本集团上市项目之联席保荐人。英皇企业融资有限公司及力高证券有限公司为整体协调人。英皇证券有限
新傳企劃公佈香港聯交所主板上市計劃
Emperor Entertainment Hotel Limited
•
Jun 29, 2023 20:34 HKT/SGT
香港知名數碼媒體旗艦集團新傳企劃有限公司(「新傳企劃」或「本集團」，股份代號：1284.HK)今天公佈其股份發售(「股份發售」)及計劃於香港聯合交易所有限公司(「香港聯交所」)主板上市之詳情。新傳企劃透過股份發售發行合共1.5億新股股份，包括1.35億股配售股份予投資者認購及1,500萬股予香港公眾認購(「股份分配」)，即分別佔總發售股份數目90%及10%。發售股份之股份分配將視乎情況重新分配，倘公開發售獲某程度的超額認購，部份股份將從配售重新分配至公開發售。英皇企業融資有限公司及力高企業融資有限公司為本集團上市項目之聯席保薦人。英皇企業融資有限公司及力高證券有限公司為整體協調人。英皇證券有限
New Media Lab Announces Proposed Listing on The Main Board of SEHK
Emperor International Holdings Limited
•
Jun 29, 2023 20:32 HKT/SGT
New Media Lab Limited ("New Media Lab" or the "Group", Stock Code: 1284.HK), a renowned digital media flagship group in Hong Kong, today announced the details of its share offer (the "Share Offer") and proposed listing on the Main Board of The Stock Exchange of Hong Kon
33rd Hong Kong Book Fair opens on 19 July
HKTDC
•
Jun 29, 2023 20:00 HKT/SGT
The 33rd HKTDC Hong Kong Book Fair, organised by the Hong Kong Trade Development Council (HKTDC), will run from 19 to 25 July (Wednesday to Tuesday) at the Hong Kong Convention and Exhibition Centre (HKCEC). With the theme of Children's and Young Adult Literature, the Book Fair will showcase ch
Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily
Soligenix, Inc
•
Jun 29, 2023 20:00 HKT/SGT
Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is excited to announce its CEO, President, and Chairman, Christopher J. Schaber, recently conducted an interview with
China Medical System Included in the First 'Sustainability Yearbook (China)' of S&P Global
China Medical System Holdings Ltd.
•
Jun 29, 2023 20:00 HKT/SGT
l CMS was included into the first "Sustainability Yearbook (China)" published by S&P Global. l Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally selected! SHENZHEN, CHINA, June 29, 2023 - (ACN Newswire) - Recently, S&P Gl
Solar Powered Sunscreen: EcoZinc a World First in Sustainable Zinc Oxide Innovation
ACN Newswire
•
Jun 29, 2023 19:00 HKT/SGT
Advance ZincTek, Australia's leading manufacturer of natural Sunscreen Actives, announces the launch of EcoZinc, the world's first solar-powered, non-nano zinc oxide powder for SPF-rated cosmetics and sunscreens. EcoZinc not only minimizes environmental impact, but also achieves a dramatic
Solar Powered Sunscreen: EcoZinc a World First in Sustainable Zinc Oxide Innovation
ACN Newswire
•
Jun 29, 2023 19:00 HKT/SGT
Advance ZincTek, Australia's leading manufacturer of natural Sunscreen Actives, announces the launch of EcoZinc, the world's first solar-powered, non-nano zinc oxide powder for SPF-rated cosmetics and sunscreens. EcoZinc not only minimizes environmental impact, but also achieves a dramatic
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
NanoViricides, Inc.
•
Jun 29, 2023 18:45 HKT/SGT
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies."We believe that the start of the Phase 1a/1b
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
NanoViricides, Inc.
•
Jun 29, 2023 18:45 HKT/SGT
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies."We believe that the start of the Phase 1a/1b